期刊文献+

TopoⅡa和Ki-67在不同分子亚型乳腺癌组织中的表达及意义 被引量:6

下载PDF
导出
摘要 目的:分析TopoⅡa和Ki-67在乳腺癌组织中的表达情况,并探讨其在不同分子亚型乳腺癌中的表达及其意义。方法:应用免疫组化EnVision二步法,检测TopoⅡa和Ki-67在253例浸润性乳腺癌组织和30例正常乳腺组织中的表达水平,并分析其在不同分子亚型乳腺癌中的表达特点。结果:乳腺癌组织中TopoⅡa和Ki-67蛋白表达明显高于正常乳腺组织(P=0.000,P=0.000)。luminal A型乳腺癌中TopoⅡa和Ki-67蛋白表达明显低于HER-2过表达型和三阴性乳腺癌组织(P=0.007,P=0.005;P=0.035,P=0.002)。乳腺癌患者TopoⅡa的表达与Ki-67呈正相关(r=0.446,P=0.000)。结论:TopoⅡa和Ki-67均可作为乳腺癌细胞增殖的标记物,对于预测各分子亚型乳腺癌的预后可能具有重要的指导意义。
出处 《实用医学杂志》 CAS 北大核心 2014年第5期778-780,共3页 The Journal of Practical Medicine
基金 汕头市医疗科技项目(编号:汕府科[2013]88号)
  • 相关文献

参考文献13

二级参考文献100

  • 1Mattila R, Alanen K, Syrjanen Immunohistochemical study on to-poisomerase II alpha, Ki-67 and cytokeratin-19 in orallichen planus lesions. Arch Dermatol Res, 2007, 298(8) :381.
  • 2Kruse A J, Gudlaugsson E, Helliesen T, et al. Evaluation of prospective, routine application of Ki-67 immunoquantitation in early (;IN for assessment of short-term progression risk. Anal Quant Cytol Histol, 2004, 26(3) : 134.
  • 3Munstedt K, von Georgi R, Franke FE. Correlation between MIB-1 determined tumor growth fraction and incidence of tumor recurrence in early ovarian carcinomas. Cancer Invest, 2004, 22(2):185.
  • 4Mayerhofer K, Lozanov P, Bodner K, et al. Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcoma. Gyne col Oncol, 2004, 92(1):175.
  • 5Akhan SE, Yavuz E, Tecer A, et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leio- myosarcomas: A clinicopathologic study. Gynecol Oncol, 2005, 99 (1):36.
  • 6Mayerhofer K, Lozanov P, Bodner K, et al. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of un-certain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Aeta Obstet Gynecol Scand, 2004, 83(11) : 1085.
  • 7Davies L, Hardin NJ, Beatty BG. Can Ki-67 predict recurrence of NO squamous cell carcinoma of the tongue? Ann Otol Rhinol Laryngol, 2006, 115(1):12.
  • 8Jalava P, Kuopio T, Juntti-Patinen L, et al. Ki67 immunohisto-chemistry: a valuable marker in prognostication but with a risk of misclassifieation: proliferation subgroups formed based on Ki67 immunoreaetivity and standardized mitotic index. Histopathology, 2006, 48(6) :674.
  • 9[1]Korshunov A, Shishikina L, Golanov A. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases [J]. Arch Pathol Lab Med,2002,126(9): 1709-1986.
  • 10[2]Nolte M, Werner M, Nasarek A et al. Expression of proliferatior associated antigens and detection of numerical chromosome aberrations in primary human liver tumors: relevance to tumor characteristicsand prognosis[J]. Clin Pathol, 1998,51(1): 47-51.

共引文献88

同被引文献47

  • 1施为建 王渝芝 蒋凤莲 等.乳腺浸润性导管癌中多药耐药相关蛋白的表达情况.中国健康月刊,2011,30(8):15-15.
  • 2O' M&lle~/ l:P,Ohf& 8,Tu D,e% &l.Topoisomer&se li alpha and responsiveness of breast cancer to adjuv&n% chemotherapy?[J].J N&tl Cancer Inst, 2009, ] 01 (9):644-650.
  • 3Park K, Kim J, Lim S, et al. Topoisomerase II-alpha ( to- poII) and HER2 amplification in breast cancers and re- sponse to preoperative doxorubicin chemotherapy [J]. Eu- ropean Journal of Cancer, 2003 (5) :631 - 634.
  • 4Andrea JE, Adachi K, Morgan AR. Fluorometric assays for DNA topoisomerases and topoisomerase-targeted drugs: quantitation of catalytic activity and DNA cleavage [J] . Molecular Pharmacology, 1991 ( 4 ) : 495 - 501.
  • 5Konecny GE, Unteh M. HER2 gene amplification and re- sponse to dose dense sequential epirubicin and paclitaxel as neoadjuvant therapy of primary breast cancer [J]. Breast Cancer Res Treat, 2006 ( 1 ) : 48.
  • 6Siddiqa A, Long LM, Li L, et al. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic pro- teins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways[J]. BMC Cancer, 2008(8) :129.
  • 7Di Leo A, Larsimont D, Gabcberg D, et al. HER-2 and topo-isomerase IIct as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide [J]. Ann Oncol, 2001(8) :1081 - 1089.
  • 8MacGrogan G, Rudolph P, De Mascarel I. DNA topoi- somerase II alpha expression and the response to primary chemotherapy in breast cancer [J]. British Journal of Cancer, 2003 (5) :666 - 671.
  • 9Tan I)S, Marchio C, Jones RL. Triple negative breast cancer: molecular profiling and prognostic impact in ad-juvant anthracycline-treated patients [J]. Breast Cancer Research and Treatment, 2008( 1 ) :27 -44.
  • 10位嘉,刘芳芳,付丽.拓扑异构酶Ⅱα在乳腺癌中的研究现状[J].中华病理学杂志,2008,37(2):132-135. 被引量:7

引证文献6

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部